OTS964 is primarily researched for its potential in cancer treatment. It functions as an inhibitor of the T-LAK cell-originated protein kinase (TOPK), which is often overexpressed in various cancer cells. By inhibiting TOPK, OTS964 can disrupt the proliferation and survival of cancer cells, making it a promising candidate for targeted cancer therapies. Preclinical studies have shown its effectiveness in reducing tumor growth in certain types of cancers, such as lung and breast cancer. Additionally, OTS964 is being explored for its ability to enhance the efficacy of other anticancer drugs when used in combination therapies. Its application is still in the experimental stage, with ongoing research to evaluate its safety, optimal dosage, and potential side effects in clinical settings.